Can a drug stop the agony of mouth sores during cancer therapy?
NCT ID NCT03387774
First seen May 27, 2026 · Last updated Jun 22, 2026 · Updated 7 times
Summary
This phase 3 trial tested whether ulinastatin, a drug that blocks certain enzymes, can reduce severe mouth sores caused by chemoradiotherapy in 179 patients with advanced nasopharyngeal cancer. Patients received either standard care or ulinastatin alongside their cancer treatment. The goal was to see if fewer patients developed painful, severe oral mucositis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ulinastatin
What this could lead to
If it works, this could provide a new way to reduce painful mouth sores during cancer treatment, improving patients' quality of life.
What could go wrong
This is a completed phase 3 trial, but results are not yet widely confirmed. The drug may not significantly reduce severe mucositis compared to standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.